Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-295 in Adult Subjects With Obesity
NCT07291232Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Nov 2025
- Primary completion
- Apr 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of GUB014295 in obesity (8 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants with Adverse Events, Number of Participants with Abnormal Change From Baseline in Vital Sign Measurements and 13 more. Started Nov 2025; status: active, not recruiting.
02
Drugs
GUB014295
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07291232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07291232.